Pfizer sticks to targets for sales of its Covid vaccines and pills this year

Pfizer shares have slid 18% since the start of the year, underperforming the broader sector

 Pfizer’s plant in Ringaskiddy was used to manufacture a new drug to combat Covid 19.

Pfizer kept its outlook for annual sales of its Covid-19 vaccine and treatment, disappointing investors who looked for the products to continue driving growth. 

While Pfizer has dominated the global market for Covid vaccines, concern remains that demand is tapering off due to excess supply. Last month, Johnson & Johnson suspended its own Covid vaccine forecast, citing a global surplus in shots.